Product Description
AI-09 is an injectable Botulinum for Glabellar Lines. AI-09 employs a proprietary technology that allows an injectable botulinum to be formulated as a convenient, ready-to-use liquid product, instead of requiring reconstitution with saline prior to use. (Sourced from: http://www.eirionthera.com/)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: Intramuscular
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shanghai Haohai Biological Technology
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Glabellar Reflex
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07321834 |
AI-09-GL-201 | P2 |
Active, not recruiting |
Glabellar Reflex |
2026-02-01 |
12% |
2026-01-08 |
Primary Endpoints|Treatments |
NCT05565950 |
AI-09-GL-101 | P2 |
Completed |
Glabellar Reflex |
2024-06-03 |
12% |
2025-08-27 |